Jaguar HealthJAGX +11.11%22 Net Margin % is 43.71% as of Mar. 2026. GuruFocus rates JAGX with a GF Score™ of 22/100. The stock has 3 warning signs investors should review. Among 946 Biotechnology companies, Jaguar Health ranks worse than 52.54% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Jaguar Health's Net Income for the
three
months ended in Mar. 2026 was $8.85 Mil. Jaguar Health's Revenue for the
three
months ended in Mar. 2026 was $20.25 Mil. Therefore, Jaguar Health's net margin for the quarter that ended in Mar. 2026 was 43.71%.
The historical rank and industry rank for Jaguar Health's Net Margin % or its related term are showing as below:
JAGX'
s Net Margin % Range Over the Past 10 Years
Min: -10376.06 Med: -483.98 Max: -115.49
Current: -115.49
JAGX's Net Margin % is ranked worse than 52.54% of 946
companies
in the Biotechnology industry
Industry Median: -88.815
vs JAGX: -115.49
Jaguar Health (NAS:JAGX) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Jaguar Health Net Margin % Related Terms
Jaguar Health Net Margin % Historical Data
* Premium members only.
The historical data trend for Jaguar Health's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Jaguar Health's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jaguar Health Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jaguar Health's Net Margin % distribution charts can be found below:
* The bar in red indicates where Jaguar Health's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jaguar Health (JAGX) has a Net Margin % of 43.71% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Jaguar Health and its competitors. According to the industry distribution chart, Jaguar Health ranks #497 out of 946 companies in the Biotechnology industry, placing it in the top 52.5%.
Is Jaguar Health's Net Margin % too high?
Jaguar Health's current Net Margin % is 43.71%. Based on the distribution chart, Jaguar Health ranks #497 out of 946 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Jaguar Health has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Jaguar Health's Net Margin % compare to BBLG and VBIO?
According to the Biotechnology industry distribution chart, Jaguar Health ranks #497 out of 946 companies for Net Margin %. This places Jaguar Health in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Jaguar Health and its competitors. Jaguar Health's current Net Margin % is 43.71%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jaguar Health stock overvalued right now?
Jaguar Health (JAGX) has a current Net Margin % of 43.71%. The current Net Margin % is 43.71%. Jaguar Health's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Jaguar Health (JAGX), the current Net Margin % is 43.71% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
22GF Score
Get the complete analysis for JAGX
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JAGX has been successfully added to your 
